ELIQUENT Life Sciences

What ELIQUENT Life Sciences does

ELIQUENT Life Sciences is a privately held professional services firm headquartered in Washington, D.C., that delivers regulatory, quality, pharmacovigilance, GxP and talent consulting to pharmaceutical, biotechnology, medical device, combination product, radiopharmaceutical and cell/gene therapy companies. The firm was assembled from six legacy consultancies — Validant, DataRevive, IDEC, Oriel, RApport and a sixth unnamed entity — and has since acquired Truliant Consulting and the consulting business of Azzur Group (the latter for $56M in March 2025 as part of Azzur's Chapter 11 restructuring). Service lines span regulatory strategy and submissions (IND, NDA, BLA, MAA), CMC, QMSR transition, inspection readiness, remediation, GxP validation and engineering, pharmacovigilance operations, regulatory policy and due diligence.

The core technology stack is human expertise rather than proprietary software, but ELIQUENT delivers implementation services on partner platforms — most prominently Veeva Safety Suite, where it served as a lead implementation partner on the June 2026 UCB go-live, migrating 14 million documents and 80 million records. Supporting assets include the IQ Central content hub, the OrielSTAT training platform, a CGT & ATMP Center of Excellence and a series of modality-specific Centers of Excellence (QMSR, radiopharmaceuticals, combination products, LDTs).

The business model is enterprise professional services, sold through direct field sales to regulated life sciences clients globally across U.S., Europe and Asia. Engagement structures include project-based consulting, Functional Service Provider (FSP), Time and Materials (T&M) and fixed-price contracts, with embedded consultant deployment under the Talent Solutions line. Pricing is quote-based and not publicly disclosed. Outcomes cited include 160+ IND submissions with a 98% success rate, 50+ breakthrough therapy applications and CMC programs claimed to compress time-to-market by 12-18 months.

Name

ELIQUENT Life Sciences

Legal name

ELIQUENT Life Sciences

Website

https://eliquent.com

Company type

Private

Operating status

Operating

Headcount range

251–500 employees

Short description

ELIQUENT Life Sciences is a privately held, Washington-based consulting firm providing regulatory affairs, quality compliance, pharmacovigilance, GxP and talent solutions to global pharmaceutical, biotech, medical device, radiopharma and cell/gene therapy companies.

Ownership category

akta.pro rank

Product category

Life Sciences Regulatory Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416), Professional, Scientific, and Technical Services (54)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Inspection Readiness & Regulatory Authority Support (FDA/EMA/MHRA) (HLAGAKAF)

akta.pro secondary industries

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Life Sciences & Biotech (R&D/Clinical) Staffing (BPACADAL), CMC, Process Development & Tech Transfer Staffing FSP (HLAGAOAK)

Keywords

• Regulatory affairs consulting
• Pharmacovigilance services
• Quality compliance consulting
• Life sciences regulatory
• GxP consulting

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Regulatory Affairs Consulting: Professional consulting services for regulatory strategy, submissions (IND, NDA, BLA, MAA), CMC solutions, and regulatory policy. Delivered by former regulators and industry experts.
2. Quality & Compliance Services: Quality systems design, inspection readiness, compliance assessments, remediation solutions, and QMSR transition support for medical device and pharmaceutical companies.
3. Pharmacovigilance & Risk Management: PV operations, safety system modernization, regulatory reporting, signal detection, and risk management planning services across the product lifecycle.
4. GxP Consulting & Implementation: Engineering solutions, validation services (CQV), reliability engineering, IT compliance, CSV, and technical staffing for GxP environments.
5. Talent Solutions: On-demand staffing and embedded consultant deployment for life sciences regulatory, quality, and technical roles.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ELIQUENT Life Sciences provides integrated regulatory, quality, and pharmacovigilance consulting services to global life sciences companies. The firm supports pharmaceutical, biotechnology, medical device, and combination product companies with regulatory strategy and submissions (IND, NDA, BLA, MAA), CMC solutions, quality systems and inspection readiness, pharmacovigilance operations and safety system modernization, GxP engineering and validation, remediation and compliance response, due diligence for transactions, and embedded talent deployment. Services are delivered by former FDA, EMA, and industry regulators and experts through project-based, FSP, T&M, and fixed-price engagement models across the U.S., Europe, and Asia.

Product overview

ELIQUENT Life Sciences is a full-service regulatory consulting firm offering an integrated platform of regulatory, quality, and safety solutions for life sciences companies. The core offering consists of six main service areas: Regulatory Affairs Solutions (covering submissions, CMC, pathway decisions, and lifecycle management), Pharmacovigilance & Risk Management Solutions (PV+), Quality & Compliance Solutions, Remediation Solutions, GxP Consulting & Implementation Solutions, and Talent Solutions. These core services are supplemented by specialized solutions including CMC Solutions, QMSR Solutions, CGT & ATMP Solutions, Drugs & Biologics Solutions, Medical Device & Diagnostics Solutions, Radiopharmaceutical Solutions, Combination Products Solutions, LDT Solutions, Industry Due Diligence Solutions, Regulatory Policy Solutions, Expert Training Solutions, and Regulatory & Medical Writing Solutions. The portfolio is delivered through a unified platform approach with cross-functional teams collaborating seamlessly across all solution areas. Supporting these services is IQ Central, a resource and knowledge platform providing industry insights, expert perspectives, and thought leadership content.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Affairs Solutions End-to-end regulatory consulting services guiding pharmaceutical, biotech, and medical device companies through regulatory submissions, from early-phase development strategy through post-approval support. Covers pipeline review, CMC strategy, clinical programs, pathway decisions, regulatory communications, marketing and labeling, and lifecycle management.
• Pharmacovigilance & Risk Management Solutions (PV+) Comprehensive pharmacovigilance services including operational harmonization, safety system modernization, compliance capabilities, technology enablement (Veeva Safety Suite implementations), organizational and talent solutions, and risk management planning across the product lifecycle.
• Quality & Compliance Solutions Quality systems design, optimization and implementation; inspectional readiness; laboratory controls and data integrity; compliance and enforcement actions support; supply chain optimization; and good clinical practices services for life sciences companies.
• Remediation Solutions Compliance assessment, rapid response, customized remediation plans, corrective action plans, implementation expertise, comprehensive regulatory communications, maintenance and monitoring, third-party reporting, and expert training services to bring operations back into compliance.
• GxP Consulting & Implementation Solutions Integrated GxP compliance solutions including engineering solutions (process development, automation, asset management, tech transfer), validation solutions (CQV, cleaning validation, process validation), reliability engineering, quality systems, IT compliance and digital validation, and technical staffing support.
• Talent Solutions Flexible talent deployment services mobilizing tailored consulting teams globally in as little as one week, providing technical credentials, region-specific expertise, and language-specific skills for on-site project support across regulatory, quality, and technical roles.

Quantifiable outcome

• 98% success rate on 160+ IND submissions
• +2 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Veeva SystemscoreTechnology or Integration · 1 June 2026Strategic collaboration for Veeva Safety Suite implementations at life sciences clients. ELIQUENT serves as implementation partner deploying pharmacovigilance transformation solutions using Veeva's cloud-based safety platform combining case processing, signal management, and reporting capabilities.
• PinnaxismajorImplementation/ SI/ Consulting Partner · 1 June 2026Collaborated with ELIQUENT and Daelight Solutions on UCB's Veeva Safety Suite implementation, representing one of the first complete suite deployments globally.
• Daelight SolutionsmajorImplementation/ SI/ Consulting Partner · 1 June 2026Collaborated on UCB's Veeva Safety Suite implementation, migrating 14 million documents and 80 million records into a single cloud-based platform.
• Azzur GroupcoreStrategic or Co-development Partner · 2 March 2025ELIQUENT acquired Azzur Group's consulting business for $56 million as part of Azzur's restructuring under Chapter 11 bankruptcy. The sale was facilitated through a court-supervised process with DIP financing support.
• RApport Global Strategic ServicescoreStrategic or Co-development Partner · 18 January 2024UK-based international regulatory consultancy acquired by ELIQUENT in January 2024. RApport's team of highly experienced professionals are experts in European regulatory pathways. The acquisition expanded ELIQUENT's European capabilities and provides clients with expanded portfolio of solutions for gaining and maintaining authorization for products in the European market.
• ValidantcoreStrategic or Co-development PartnerOne of six global life science consultancies merged to form ELIQUENT. Validant is a full-service life science consulting firm serving developers and manufacturers of pharmaceuticals, biologics, medical devices, and diagnostics worldwide.
• DataRevivecoreStrategic or Co-development PartnerOne of six firms merged to form ELIQUENT. A regulatory strategy and consultancy firm focused on supporting pharma and biotech to navigate the regulatory approval pathway for global clients in the U.S. market with deep real-world regulatory, CMC, preclinical, clinical, and GxP expertise.
• IDECcoreStrategic or Co-development PartnerOne of six firms merged to form ELIQUENT. Regionally specialized regulatory guidance and end-to-end drug product support for pharmaceutical innovators seeking approval in the Japanese market.
• OrielcoreStrategic or Co-development PartnerOne of six firms merged to form ELIQUENT. A global leader in training and consulting for business process improvement, regulatory compliance, and quality management systems supporting life sciences companies' programs for compliance with FDA and international regulations.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ProPharma Group: ProPharma Group is a pure-play life-sciences regulatory, compliance, and pharmacovigilance consultancy serving pharma, biotech, and medical device sponsors. It is the most directly comparable mid-market competitor to ELIQUENT in scope, delivery model, and customer base.
• PharmaLex (Cencora PharmaLex): PharmaLex (acquired by Cencora/AmerisourceBergen) is a global regulatory affairs, pharmacovigilance, and quality consulting firm. It directly competes with ELIQUENT on regulatory strategy, submissions, and PV services across the same pharmaceutical and biotech customer base.
• Voisin Consulting Life Sciences (VCLS): VCLS is a healthcare and life-sciences regulatory consultancy with strong European presence offering regulatory strategy, clinical development, and health-economics consulting. Comparable to ELIQUENT in its combination of regulatory specialization and trans-Atlantic reach.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with a regulatory and pharmacovigilance consultancy arm serving pharma and biotech sponsors. Comparable in scale and customer profile to ELIQUENT, with similar emphasis on complex therapeutic areas.

Broad incumbents

• Parexel International: Parexel is a global CRO that bundles regulatory affairs, pharmacovigilance, and quality services alongside clinical operations. As a larger incumbent, it overlaps with ELIQUENT on regulatory consulting but as part of a broader clinical services portfolio.
• IQVIA: IQVIA is the largest global CRO with extensive regulatory and quality consulting capabilities bolted onto its clinical, real-world evidence, and technology platforms. It competes with ELIQUENT for enterprise regulatory mandates but as one offering among many.
• ICON plc: ICON provides global CRO services including dedicated regulatory affairs and pharmacovigilance units. It is an incumbent competitor for ELIQUENT on regulatory and PV engagements, especially with large pharmaceutical sponsors seeking vendor consolidation.
• Charles River Laboratories: Charles River Laboratories offers regulatory and quality consulting alongside its broader discovery, safety assessment, and manufacturing services. It is a broader-life-sciences incumbent whose regulatory unit overlaps meaningfully with ELIQUENT's quality and GxP practices.

Emerging players

• KCR (kcr): KCR is a European-headquartered CRO and regulatory/clinical consultancy with growing global reach. It overlaps with ELIQUENT on regulatory affairs and PV services, particularly for European biotech sponsors, but remains a smaller emerging player.
• Clinipace Worldwide: Clinipace is a mid-market CRO providing regulatory, clinical, and biostatistics services to emerging and mid-sized biopharma. It intersects with ELIQUENT on regulatory consulting for biotech sponsors and operates as an emerging niche competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eliquent-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ELIQUENT Life Sciences